Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VRC-HIVDNA009-00-VP
- Development stage
- Phase 2
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
VRC-HIVDNA009-00-VP is a multiclade HIV-1 DNA plasmid vaccine developed by the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID). The vaccine is a mixture of four DNA plasmids: one encoding a Gag-Pol-Nef fusion protein from HIV-1 clade B, and three encoding modified Envelope (Env) glycoproteins from clades A, B, and C. These clades represent approximately 90% of new HIV infections globally. The vaccine is designed to elicit both humoral (antibody) and cellular (CD4+ and CD8+ T cell) immune responses against HIV. It has been evaluated in clinical trials as a standalone preventive vaccine, a therapeutic vaccine in HIV-infected individuals on antiretroviral therapy, and as a priming agent in prime-boost regimens, frequently followed by an adenoviral vector boost such as VRC-HIVADV014-00-VP.
- Other names
- VRC 004VRC004VRC-004multiclade HIV-1 DNA vaccineGag-Pol-Nef-multiclade Env DNA vaccine
02
Targets
gp41 (Human immunodeficiency virus type 1 glycoprotein 41)Gag (HIV-1 Gag polyprotein)Nef (HIV-1 Nef)Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on VRC-HIVDNA009-00-VP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VRC-HIVDNA009-00-VP.